REFERENCES
  1. Young-Xu Y, van Aalst R, Russo E, Lee JKH, Chit A. The annual burden of seasonal influenza in the US veterans affairs population. PLoS One 2017;12:e0169344.
  2. Lee DH, Bertran K, Kwon JH, Swayne DE. Evolution, global spread, and pathogenicity of highly pathogenic avian influenza H5NX clade 2.3.4.4. J Vet Sci 2017;18:269-280.
  3. Peiris JSM, de Jong MD, Guan Y. Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev 2007;20:243-267.
  4. Yang L, Zhu W, Li X, Chen M, Wu J, Yu P, Qi S, Huang Y, Shi W, Dong J, Zhao X, Huang W, Li Z, Zeng X, Bo H, Chen T, Chen W, Liu J, Zhang Y, Liang Z, Shi W, Shu Y, Wang D. Genesis and spread of newly emerged highly pathogenic H7N9 avian viruses in mainland China. J Virol 2017;91:e01277-01217.
  5. Saunders-Hastings PR, Krewski D. Reviewing the history of pandemic influenza: understanding patterns of emergence and transmission. Pathogens 2016;5:66.
  6. World Health Organization (WHO). Influenza (seasonal). November 6, 2018. https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal) Accessed 14 Nov 2019.
  7. Soema PC, Kompier R, Amorij JP, Kersten GFA. Current and next generation influenza vaccines: formulation and production strategies. Eur J Pharm Biopharm 2015;94:251-263.
  8. De Clercq E. 2006. Antiviral agents active against influenza a viruses. Nat Rev Drug Discov 2006;5:1015-1025.
  9. Hussain M, Galvin HD, Haw TY, Nutsford AN, Husain M. Drug resistance in influenza A virus: the epidemiology and management. Infect Drug Res 2017;10:121-134.
  10. Heider H, Adamczyk B, Presber HW, Schroeder C, Feldblum R, Indulen MK. Occurrence of amantadine- and rimantadine-resistant influenza A virus strains during the 1980 epidemic. Acta Virol 1981;25:395-400.
  11. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 2009;48:S3-S13.
  12. Centers for Disease Control and Prevention (CDC). CDC recommends against the use of amantadine and rimantadine for the treatment or prophylaxis of influenza in the United States during the 2005-06 influenza season 2006. https://stacks.cdc.gov/view/cdc/25151 Accessed November 14, 2019.
  13. Gubareva LV, Besselaar TG, Daniels RS, Fry A, Gregory V, Huang W, Hurt AC, Jorquera PA, Lackenby A, Leang SK, Lo J, Pereyaslov D, Rebelo-de-Andrade H, Siqueira MM, Takashita E, Odagiri T, Wang D, Zhang W, Meijer A. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015–2016. Antiviral Res 2017;146:12-20. https://https://doi.org/10.1016/j.antiviral.2017.08.004.
  14. Lina B, Boucher C, Osterhaus A, Monto AS, Schutten M, Whitley RJ, Nguyen-Van-Tam JS. Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the influenza resistance information study. Influenza Other Respir Viruses 2018;12:267-278.
  15. CDC. Influenza antiviral drug resistance 2019. https://www.cdc.gov/flu/treatment/antiviralresistance.htm Accessed Nov 14, 2019.
  16. Public Health England (PHE). PHE guidance on the use of antiviral agents for the treatment and prophylaxis of seasonal influenza, 10 2019. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/833572/PHE_guidance_antivirals_influenza_201920.pdf Accessed November 14, 2019.
  17. Zhirnov OP, Bokova NO, Isaeva EI, Vorobieva IV, Malyshev, NA. Pathogenetic treatment of influenza patients with aerosolized form of aprotinin, a protease inhibitor. BIOpreparations. Prevention, Diagnosis, Treatment 2015;4:59-64.
  18. Zhirnov OP, Golyando PB, Ovcharenko AV. Replication of influenza B virus in chicken embryos is suppressed by exogenous aprotinin. Arch Virol 1994;135:209-216.
  19. Zhirnov OP, Klenk HD, Wright PF. Aprotinin and similar protease inhibitors as drugs against influenza. Antiviral Res 2011;92:27-36.
  20. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Epidemiol 1938;27:493-497.
  21. Kawai N, Ikematsu H, Iwaki N, Maeda T, Satoh I, Hirotsu N, Kashiwagi S. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003–2004 and 2004–2005 influenza seasons. Clin Infect Dis 2006;43: 439-444.
  22. Sato M, Saito R, Sato I, Tanabe N, Shobugawa Y, Sasaki A, Li D, Suzuki Y, Sato M, Sakai T. Effectiveness of oseltamivir treatment among children with influenza A or B virus infections during four successive winters in Niigata city, Japan. Tohoku J Exp Med 2008;214:113-120.
  23. Zhirnov OP, Ikizler MR, Wright PF. Cleavage of influenza A virus hemagglutinin in human respiratory epithelium is cell associated and sensitive to exogenous antiproteases. J Virol 2002;76:8682.
  24. Zhirnov OP, Matrosovich TY, Matrosovich MN, Klenk HD. Aprotinin, a protease inhibitor, suppresses proteolytic activation of pandemic H1N1v influenza virus. Antivir Chem Chemother 2011;21:169-174.
  25. Ovcharenko AV, Zhirnov OP. Aprotinin aerosol treatment of influenza and paramyxovirus bronchopneumonia of mice. Antiviral Res 1994;23:107-118.
  26. Fritz H, Jochum M. Aprotinin and its target enzymes in vitro and in vivo. In: Birnbaum DE, Hoffmeister HE, ed. Blood saving in open heart surgery: 9th annual meeting of the International Society for Heart Transplantation . Schattauer, Munich, Germany, 1989:42-51.
  27. Peacock PT, James J, Sealy EJ, Iqbal M. A global perspective on H9N2 avian influenza virus. Viruses 2019;11:620.
  28. Nam JH, Kim EH, Song D, Choi YK, Kim JK, Poo H. Emergence of mammalian species-infectious and -pathogenic avian influenza H6N5 virus with no evidence of adaptation. J Virol 2011;85:13271.
  29. Nam JH, Shim SM, Song EJ, Españo E, Jeong DG, Song D, Kim JK. Rapid virulence shift of an H5N2 avian influenza virus during a single passage in mice. Arch Virol 2017;162:3017-3024.
  30. Burnham AJ, Baranovich T, Govorkova EA. Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance. Antiviral Res 2013;100:520-534.
  31. Royston D, De Hert S, van der Linden J, Ouattara A, Zacharowski K. A special article following the relicence of aprotinin injection in Europe. Anaesth Crit Care Pain Med 2017;36:97-102.
  32. Davis R, Whittington. Aprotinin. Drugs 1995;49;954-983.
  33. Emerson Jr TE. Pharmacology of aprotinin and efficacy during cardiopulmonary bypass. Cardiovasc Drug Rev 1989;7:127-140.
  34. Zhirnov OP, Ovcharenko AV, Bukrinskaya AG. Suppression of influenza virus replication in infected mice by protease inhibitors. J Gen Virol 1984;65:191-196.
  35. Erasmus Medical Centre, Istituto Zooprofilattico Sperimentale delle Venezie, Richard M, Fouchier R, Monne I, Kuiken T. Mechanisms and risk factors for mutation from low to highly pathogenic avian influenza virus. EFSA Supporting Publications 2017;14:1287E.